Explore approved therapies and drugs in development for fibrosis and inflammation, including their preclinical models.
abituzumab
SSc
Merck KGaA
Anti-CD146 monoclonal antibody
fresolimumab
FSGS / DKD
Sanofi / Genzyme
Anti-TGF-beta monoclonal antibody
tanzisertib
IPF
Celgene
JNK inhibitor
zinpentraxin-alfa
Roche / Promedior
Recombinant human pentraxin-2 (PTX-2)
gb0139
Galecto
Galectin-3 inhibitor
stm-434
Acceleron Pharma
Activin receptor ligand trap
pbi-4050
Liminal BioSciences
GPR40 agonist / GPR84 antagonist
bexotegrast
Pliant Therapeutics
Dual integrin αvβ6 / αvβ1 inhibitor
pamrevlumab
IPF / Pancreatic Cancer
FibroGen
Connective Tissue Growth Factor (CTGF) inhibitor
resmetirom
MASH
Madrigal Pharmaceuticals
Thyroid hormone receptor beta (THR-β) selective agonist
nerandomilast
Kyorin Pharmaceutical
Phosphodiesterase 4 (PDE4) inhibitor, reduces inflammation and fibrosis
pirfenidone
Genentech (Roche)
Anti-fibrotic and anti-inflammatory properties, modulates TGF-β and TNF-α
nintedanib
IPF / SSc-ILD
Boehringer Ingelheim
Multi-kinase inhibitor targeting VEGFR, FGFR, and PDGFR pathways
Semaglutide
MASH / Obesity
Novo Nordisk
Unknown
Tirzepatide
Eli Lilly
Survodutide
Efruxifermin
Akero Therapeutics
Lanifibranor
Inventiva
Pegozafermin
89bio
Denifanstat
Sagimet Biosciences
Retatrutide
Pemvidutide
Altimmune
Orforglipron
Obesity / MASH
VK2809
Viking Therapeutics
FDA承認速報・治験結果・前臨床モデル選択・アッセイ最適化。ベンチからパイプラインまで、必要な情報だけをキュレーション。月2通まで。
登録によりプライバシーポリシーに同意したものとみなします。月最大2通。ワンクリックで解除可。